Core Insights - The animal health sector experienced a decline of 0.47% on October 28, with Shenyuan Biological leading the drop [1][2] - The Shanghai Composite Index closed at 3988.22, down 0.22%, while the Shenzhen Component Index closed at 13430.1, down 0.44% [1] Stock Performance - Zhongmu Co., Ltd. (600195) saw a closing price of 7.78, with an increase of 4.71% and a trading volume of 346,700 shares, amounting to a transaction value of 269 million yuan [1] - Xianfeng Holdings (002141) closed at 4.16, up 2.72%, with a trading volume of 394,400 shares [1] - Ruipu Biological (300119) closed at 21.55, up 1.03%, with a trading volume of 127,300 shares [1] - Shenyuan Biological (688098) closed at 10.30, down 6.36%, with a trading volume of 168,900 shares and a transaction value of 176 million yuan [2] - Biological Shares (600201) closed at 10.63, down 4.06%, with a trading volume of 380,700 shares [2] Capital Flow - The animal health sector saw a net outflow of 81.39 million yuan from institutional investors, while retail investors had a net inflow of 71.62 million yuan [2][3] - The capital flow for individual stocks showed that Ruipu Biological had a net inflow of 15.04 million yuan from institutional investors, while it faced a net outflow of 25.78 million yuan from retail investors [3] - Shenyuan Biological experienced a net outflow of 5.53 million yuan from institutional investors, with a net inflow of 6.62 million yuan from retail investors [3]

Core Viewpoint - The vaccine industry is showing significant growth in the first three quarters of the year, with various vaccine types, including circular, diarrhea, brucellosis, and cat trivalent vaccines, continuing to perform well [1][2] Vaccine Batch Issuance - In the first three quarters, most vaccine types have seen substantial year-on-year growth, with specific increases in pig vaccines such as foot-and-mouth disease (+9.1%), circular vaccine (+29.5%), pseudorabies vaccine (+27.0%), and swine fever vaccine (+17.7%) [1] - Poultry vaccines like avian influenza trivalent vaccine (+9.6%) and Newcastle disease vaccine (+12.4%) also showed stable growth, while brucellosis vaccine experienced a remarkable increase of +60.2% [1][2] - Pet vaccines, particularly domestic rabies vaccine (+22.8%) and domestic cat trivalent vaccine (+74.4%), have maintained high growth rates [1] Factors Driving Growth - The growth in pig vaccines is attributed to multiple factors, including farming profitability, increased pig slaughter rates, and the introduction of new products [2] - The poultry vaccine sector continues to grow steadily, while the brucellosis vaccine benefits from the ongoing launch of new products [2] Veterinary Drug Raw Materials - As of October 22, the Veterinary Pharmaceutical Index (VPI) stands at 69.29, reflecting a 0.1% increase from the end of September and a 6.4% increase year-on-year [3] - The VPI index has shown a positive trend in October, with an average of 69.33, marking a 0.9% increase from September [3][4] Price Trends and Market Dynamics - The price of veterinary raw materials has been on the rise due to tightened supply and increased demand from large orders, particularly for products like tylosin [4] - The overall price increase in veterinary raw materials is driven by a combination of cost factors, corporate strategies, and market demand [4] Investment Recommendations - The industry is gradually recovering from a downturn, with a focus on undervalued companies that exhibit both elasticity and certainty [5] - Companies that have shown strong performance typically possess innovative qualities in product development, marketing strategies, or capital operations [6] - Recommended companies for investment include Ruipu Biological (300119.SZ), Kexin Biological (688526.SH), and others [6]

Group 1 - The event "International Industrial Investment Cooperation Docking Activity - Henan Station" was successfully held in Luoyang, guided by the National Development and Reform Commission and the Henan Provincial Government, with participation from over 100 domestic and foreign enterprises and associations [1][3] - The theme of the event was "Global Industrial Chain · Regional New Pivot," aiming to promote international industrial investment cooperation in key areas and provide an efficient platform for foreign enterprises to develop in China [3][4] - Keynote speeches highlighted Henan's strategic importance as a major population, economic, and agricultural province, with a focus on collaboration in pharmaceuticals, high-end medical devices, and logistics [3][4] Group 2 - The event featured multiple segments including main activities, specialized docking, project signing, and site visits, facilitating in-depth exchanges on cooperation paths and opportunities among over 100 representatives from various enterprises [4][5] - During the event, 11 cooperation projects were signed, covering high-end manufacturing, healthcare, and modern logistics sectors, indicating strong interest in collaboration [4][5] - The International Cooperation Center plans to continue building platforms for international industrial investment cooperation and optimizing services for foreign investment [5]

Investment Rating - The report maintains a "Recommendation" rating for the animal health industry, expecting the industry index to outperform the benchmark index by more than 5% in the next 3-6 months [2][82]. Core Insights - The animal health industry has shown significant growth in vaccine issuance, with most vaccine varieties experiencing year-on-year increases in the first three quarters of the year. Key vaccines such as porcine epidemic diarrhea, porcine circovirus, and others have demonstrated strong performance [9][12]. - The Veterinary Product Index (VPI) has shown a continued upward trend in October, indicating a recovery in raw material prices for veterinary drugs after a period of decline [3][58]. - The report highlights that the industry is gradually emerging from a low point, with a focus on undervalued companies that exhibit both elasticity and certainty in their performance [71][72]. Summary by Sections Vaccine Issuance - Cumulative data from January to September shows that most vaccine varieties have experienced significant year-on-year growth, particularly in porcine vaccines, with increases of 9.1% for foot-and-mouth disease vaccine, 29.5% for porcine circovirus vaccine, and 60.2% for brucellosis vaccine [9][12]. - The report notes that the growth in vaccine issuance is driven by multiple factors, including farming profitability, increased slaughter rates, and the introduction of new products [13][14]. Raw Material Prices - As of October 22, the VPI stands at 69.29, reflecting a 0.1% increase from the end of September and a 6.4% increase year-on-year. This marks a recovery after three consecutive months of decline [58][61]. - The report indicates that the prices of most veterinary raw materials have improved, with significant increases noted for products like Tylosin and Amoxicillin [59][61]. Investment Recommendations - The report suggests focusing on companies that have shown resilience and innovation, such as Reap Bio, Kexin Bio, and others, as they are expected to perform well in the recovering market [71][73]. - It emphasizes that the competitive landscape is shifting, with larger companies likely to outperform smaller ones, leading to potential consolidation in the industry [72][73].

Core Insights - The animal health sector experienced a rise of 1.56% on October 27, with Huisheng Biological leading the gains [1] - The Shanghai Composite Index closed at 3996.94, up 1.18%, while the Shenzhen Component Index closed at 13489.4, up 1.51% [1] Stock Performance Summary - Huisheng Biological (300871) closed at 21.69, up 4.53% with a trading volume of 105,300 shares and a turnover of 227 million yuan [1] - Xianfeng Holdings (002141) closed at 4.05, up 3.32% with a trading volume of 503,300 shares and a turnover of 203 million yuan [1] - Biological Shares (600201) closed at 11.08, up 2.88% with a trading volume of 444,500 shares and a turnover of 489 million yuan [1] - Other notable stocks include Shunlian Biological (688098) at 11.00, up 2.33%, and Ruipu Biological (300119) at 21.33, up 2.20% [1] Capital Flow Analysis - The animal health sector saw a net inflow of 91.28 million yuan from institutional investors, while retail investors experienced a net outflow of 1.02 billion yuan [2] - Major stocks like Biological Shares (600201) had a net inflow of 64.91 million yuan from institutional investors, while Huisheng Biological (300871) saw a net inflow of 24.29 million yuan [3] - Conversely, *ST Green Kang (002868) experienced a significant net outflow of 4.93 million yuan from institutional investors [3]

Core Insights - The international industrial investment cooperation event in Luoyang, held on October 23-24, aimed to deepen Sino-foreign cooperation and strengthen industrial connections, focusing on high-quality development in manufacturing, service industry expansion, and sovereign wealth funds [1][2] Group 1: Event Overview - Over 100 renowned domestic and foreign enterprises, business associations, and financial institutions participated, transforming Luoyang into a "global industrial chain docking hall" [1] - The event was guided by the National Development and Reform Commission and the Henan Provincial Government, emphasizing practical cooperation and communication between multinational companies and the central region [1][2] Group 2: Regional Advantages - Henan's unique advantages include convenient transportation, significant market potential, favorable basic conditions, and an excellent policy environment, making it an attractive destination for multinational enterprises [2] - The region is a key starting point for the "Air Silk Road," with policies such as free trade zones and comprehensive bonded zones enhancing its appeal [2] Group 3: Investment Opportunities - The National Development and Reform Commission announced a new policy package to encourage foreign investment, including a forthcoming updated directory for foreign investment industries and easier access for sovereign wealth fund investments [3] - Companies like Knorr have established a strong presence in Henan, showcasing successful collaborations in local infrastructure projects, indicating a trend of deepening partnerships [3][4] Group 4: Collaboration Outcomes - Eleven cooperation agreements were signed, focusing on capital cooperation, energy transition, and technological innovation, reflecting a commitment to building trust and expectations for future collaboration [3][4] - Companies expressed confidence in expanding their projects in Henan, with plans to replicate successful models in other areas of the province [4][5]

Core Insights - Beijing Zhongke Gene Technology Co., Ltd. (Zhongke Gene) has disclosed its progress report on the guidance for its initial public offering (IPO) [2] - The guidance agreement with Guotai Junan was signed in March 2021, with the guidance period set from July 2025 to September 2025 [2] Company Overview - Zhongke Gene was established on April 22, 2016, and specializes in third-party veterinary testing services, veterinary diagnostic products, and related biological materials [2] - The company is one of the first independent third-party veterinary testing laboratories in China to obtain CMA certification [2] - The registered capital of Zhongke Gene is 93.2819 million yuan [2] Ownership Structure - The actual controller of Zhongke Gene is Zhang Xuke, who holds a total shareholding ratio of 35.58% and a voting power of 78.48% [2] - Other shareholders include PlaiKe, CITIC Agriculture, Da'an Gene, and Wantai Biological Pharmacy [2] Leadership Profile - Zhang Xuke has a bachelor's degree and is a researcher with special government allowances [4] - He has held various positions, including veterinarian at the Luoyang Railway Veterinary Quarantine Station and executive director at Luoyang PlaiKe Biological Engineering Co., Ltd. [4] - Currently, he serves as the chairman of the fifth board of directors of PlaiKe and holds several leadership roles in veterinary associations [4]

Core Viewpoint - The animal health sector experienced a slight increase of 0.21% on October 24, with significant contributions from specific stocks, particularly Biological Shares, which led the gains [1] Market Performance - The Shanghai Composite Index closed at 3950.31, up 0.71% - The Shenzhen Component Index closed at 13289.18, up 2.02% [1] Stock Performance in Animal Health Sector - Biological Shares (600201) closed at 10.77, up 2.87% with a trading volume of 311,900 shares and a turnover of 333 million yuan - Other notable stocks include: - *ST Green Health (002868): closed at 29.09, up 0.66% - Shunlian Biological (688098): closed at 10.75, up 0.66% - Huisheng Biological (300871): closed at 20.75, up 0.48% - Yongshun Biological (920729): closed at 9.68, up 0.31% - Jinhe Biological (002688): closed at 6.68, unchanged [1] Capital Flow Analysis - The animal health sector saw a net inflow of 8.6031 million yuan from institutional investors, while retail investors experienced a net outflow of 24.4195 million yuan [2] - The breakdown of capital flow indicates: - Repu Biological (300119) had a net inflow of 9.2707 million yuan from institutional investors - Biological Shares (600201) saw a net inflow of 8.4244 million yuan - Kexin Biological (688526) had a net inflow of 5.4428 million yuan from institutional investors [3]

Core Viewpoint - The animal health sector experienced a decline of 0.36% on October 22, with Dayu Biological leading the drop. The Shanghai Composite Index closed at 3913.76, down 0.07%, while the Shenzhen Component Index closed at 12996.61, down 0.62% [1]. Stock Performance Summary - The following stocks in the animal health sector showed varied performance: - Shengwu Co. (600201) closed at 10.78, up 0.56% with a trading volume of 327,000 shares and a turnover of 351 million yuan - Ruipu Biological (300119) closed at 21.50, up 0.51% with a trading volume of 73,200 shares and a turnover of 158 million yuan - Haili Biological (603718) closed at 7.04, up 0.28% with a trading volume of 44,200 shares and a turnover of 31.17 million yuan - Dayu Biological (920970) closed at 9.46, down 1.25% with a trading volume of 20,800 shares and a turnover of 19.89 million yuan - ST Lvkang (002868) closed at 28.49, down 1.18% with a trading volume of 9,904 shares and a turnover of 28.26 million yuan [1][2]. Capital Flow Analysis - The animal health sector saw a net outflow of 47.45 million yuan from institutional investors, while retail investors contributed a net inflow of 36.66 million yuan. Speculative funds recorded a net inflow of 10.80 million yuan [2][3]. - Specific stock capital flows included: - Shunlian Biological (688098) had a net inflow of 6.94 million yuan from institutional investors but a net outflow of 12.58 million yuan from retail investors - Ruipu Biological (300119) experienced a net outflow of 2.94 million yuan from institutional investors, with a significant net inflow of 13.74 million yuan from speculative funds [3].

Group 1 - The core viewpoint indicates that the pig farming industry is facing multiple pressures, including declining market prices, rising epidemic risks, and policy guidance, leading to an expected increase in the motivation for capacity reduction [1] - As of the end of Q3 2025, the number of breeding sows in China is reported at 40.35 million, a year-on-year decrease of 280,000 and a quarter-on-quarter decrease of 90,000 [1] - The Pacific Securities report highlights that the valuations of most listed breeding companies are at historical lows, suggesting significant potential for long-term investment value as they are still within the historical bottom range [1] Group 2 - As of September 30, 2025, the top ten weighted stocks in the China Livestock Breeding Index account for 66.06% of the index, with major companies including Muyuan Foods, Wens Foodstuff Group, and Haida Group [2]